XH-001 is under clinical development by NeoCura Bio-Medical Technology and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XH-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XH-001 overview
XH-001 is under development for the treatment advanced solid tumors. It is an mRNA-based tumor neoantigen vaccine and is being developed based on NeoCura Ag, an artificial intelligence (AI) technology.
NeoCura Bio-Medical Technology overview
NeoCura Bio-Medical Technology (NeoCura) formerly Shenzhen NeoCura Biotechnology (NeoCura) is an developer of an artificial intelligence (AI) medical platform intended to improve the precision diagnosis and treatment of tumor. NeoCura is headquartered in Shenzhen, Guangdong, China.
For a complete picture of XH-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
